Sunday, May 5, 2024
Home Research Page 3

Research

    Random

    Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

    Biotech News Editor / Curator -
    Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE
    CPRE Networks

    Adding VYRE Network (CAPV) to the Watch List.

    Research Editor / Curator -
    Look What We Found. Our First Internet Play in Ages, And It's a Doozy. We would categorize this...
    nanovibronix, biotech stock review

    Biotech Stock Review Adds NanoVibronix (NAOV) $2.95, to Watch List.

    Biotech News Editor / Curator -
    NanoVibronix Announces Closing of $3.2 Million Private Placement to Existing Shareholders. Adding to Watch List @ $2.95*...

    Adding Asia Broadband (AABB) to Speculative Watch List.

    Research Editor / Curator -
    Asia Broadband, Gold Play With Digital Currency (NFT) Twist The last speculative stock trading under $0.05, that we...
    Draganfly

    Draganfly (DFLYF) Holds ‘Pole Position’ in Race for Drone Supremacy After Chinese Barred from...

    Research Editor / Curator -
    STREETWISE REPORTS - March 3, 2020 The company establishes a toehold with U.S....

    Primer: Quantitative Easing, MMT, and Inflation/Deflation, Lyn Alden.

    Stand Down. Editor / Curator -
    Quantitative easing (QE) occurs when central banks, such as the U.S. Federal Reserve, create new money to buy government bonds or other...

    GeoVax (GOVX) Research Reports Archive

    Research Editor / Curator -
    Research Report Archive Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research....

    Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.

    Research Editor / Curator -
    The 2021 Biotech Six Pack: Stocks We Expect to Double! These are ideas #3 and #4 for the 'Biotech...

    Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...

    Research Editor / Curator -
    New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
    Mitesco

    Report on Mitesco (MITI): Zacks Issues $0.53 Price Target, a 165% Potential Gain.

    Research Editor / Curator -
    LIVE QUOTE Original Report: Initiating Coverage...
    1234...8Page 3 of 8

    Latest article

    We’re in Tampa for the Kentucky Derby.

    2024 Watch List Editor / Curator -
    GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.